More News

11 July 2013

Nuvilex Completes Acquisition of Exclusive Worldwide Rights to Pancreatic Cancer Treatment Technology

10 July 2013

UCB gets access to rights for an antibody programme from WILEX for non-oncology indications

10 July 2013

Loxo Oncology And Array BioPharma Announce License And Collaboration Agreement

9 July 2013

Amgen And Servier Announce Product Collaboration

9 July 2013

uniQure Signs EU Commercialization Agreement With Chiesi Farmaceutici for First Approved Gene Therapy Treatment, and Announces EUR 45 Million (USD 58 Million) in Equity and Collaboration Financing

9 July 2013

Acorda Therapeutics Announces Acquisition of Two Neuropathic Pain Assets

9 July 2013

Immunocore signs research and licensing agreement with GlaxoSmithKline to discover ImmTACs against novel targets

9 July 2013

AstraZeneca collaborates with Cambridge medical research institutions to advance cancer research

8 July 2013

RaNA Therapeutics, Inc. and Santaris Pharma A/S announce agreement to develop RNA-targeted medicines that selectively activate protein expression

8 July 2013

Capricor and Nile Therapeutics Announce Merger Agreement

8 July 2013

OncoEthix Closes 18 Million CHF (USD 19 Million) Series B Financing

8 July 2013

Novartis and Biological E agree to deliver affordable vaccines for typhoid and paratyphoid A fevers to developing world

5 July 2013

UCB to out-license olokizumab to R-Pharm

3 July 2013

SK Biopharmaceuticals and AriBio Enter into a Strategic Alliance

3 July 2013

Blaze Bioscience and Fred Hutchinson Cancer Research Center Enter into Collaboration and Option Agreement in Support of Optides Discovery Program

3 July 2013

Transgene Grants Ascend Biopharmaceuticals a License to TG1042, an Immunotherapy to Treat Basal Cell Carcinoma, a Common Type of Skin Cancer

3 July 2013

Avanir Pharmaceuticals and OptiNose Announce Development and Commercialization Agreement for a New Fast-Acting Investigational Product for the Treatment of Acute Migraine

2 July 2013

BioInvent extends collaboration for the discovery and development of therapeutic antibodies with Mitsubishi Tanabe

1 July 2013

PHYLOGICA EXPANDS COLLABORATION WITH JANSSEN FOR PEPTIDE-DRUG CONJUGATES

27 June 2013

Immunocore and Genentech enter strategic alliance

27 June 2013

Janssen And Johnson & Johnson Innovation Announce First-Of-Its-Kind Inflammatory Bowel Disease Research Alliance With The Icahn School Of Medicine At Mount Sinai

27 June 2013

Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of an Additional Antibody-Drug Conjugate (ADC) Under Existing Collaboration

27 June 2013

MorphoSys and Celgene Create Strategic Alliance to Advance CD38 Cancer Program MOR202 for Patients with Multiple Myeloma

26 June 2013

Karo Bio Announces Extension of Existing Collaboration with Pfizer to Discover and Develop Drugs for Autoimmune Diseases

26 June 2013

EMD Serono Establishes Immuno-Oncology Research and Early Development Platform to Advance Innovation in Cancer Therapies

25 June 2013

Cytokinetics And ASTELLAS Announce Collaboration in The Field of Skeletal Muscle Activation

25 June 2013

Seattle Genetics Enters Into New Antibody-Drug Conjugate Collaboration with Bayer

25 June 2013

XL-protein and GENERIUM sign broad therapeutic license and collaboration agreement to develop PASylated therapeutics for the Russian Federation

24 June 2013

VivaMab and ADC Therapeutics Announce Antibody Licensing Deal for Novel ADC Candidate to Target Hematologic Cancers

19 June 2013

Teva Strengthens Respiratory Franchise with Acquisition of MicroDose Therapeutx

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Ustekinumab (Stelara) Biosimilars Pipeline Review

5T4-Targeted Immunotherapy Candidates Pipeline Review

B7-H3-Targeted Immunotherapy Candidates Pipeline Review

Blockbuster Biologics 2019: Sales of Recombinant Therapeutic Antibodies & Proteins

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders, Technologies, Pipeline and Partnering from an Industry Perspective

Pembrolizumab (Keytruda) Biosimilar Antibody Pipeline Review

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Report Package: Bispecific Antibodies